ABSTRACT
INTRODUCTION
In general, headache is a frequent symptom in the population, with a lifetime prevalence of 93% in men and 99% in women. Headache is the main reason for neurological consultations in outpatient care. It is estimated that 5 to 10% of the population seek medical attention during their lifetime due to headache 1, 2 . The main primary headaches are of the tensional type and the migraine. Migraine is a type of cranial pain lasting from 4 to 72 hours, characterized by strong intensity, throbbing or pulsatile, worsening with daily activities, being unilateral in 2/3 of the cases, and may be accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia. There may be five detectable phases in a typical migraine attack: prodrome or premonitory symptoms, aura, headache, associated symptoms (nausea, photophobia) and postdrome (fatigue, exhaustion)
Patients with chronic pain often report cognitive complaints that impair their social situations and activities of daily living. According to a meta-analysis published in 2013, the authors concluded that there is a greater change in cognitive tests of patients with chronic pain when compared to normal volunteers, despite the significant heterogeneity of the studies included in the analysis 6 . It was also suggested that future research is done as well as standardized testing methods. Several studies have analyzed the association between migraine and cognitive function, but the results of these studies are diverse. Some cross-sectional studies found no difference between patients with migraine and controls [7] [8] [9] [10] [11] , while others demonstrated evidence of worse cognitive performance among migraine patients [12] [13] [14] [15] . Several tests were used to assess cognitive function, and many of these studies were small, which may limit their ability to detect differences between groups. Conventional magnetic nuclear resonance (MNR) studies have discovered that patients with migraine have an increased risk of ischemic lesions in the white matter, sometimes referred to as the "substrate for migraine". This risk exists for patients with and without aura, and it is being increased in patients with migraine with aura and chronic migraine. Cumulative migraine effects on the central nervous system (CNS) have been demonstrated, although the functional implication of these results remains unclear. In the long term, it is believed that these lesions would cause cognitive deficits in these patients 16 . There are important confusing factors when evaluating a patient with migraine and cognitive complaints. First of all, many of these patients present depressive disorder or anxiety disorder, comorbidities that are related to attention deficit and impaired performance in cognitive tests. Secondly, some drugs commonly used by patients with migraine, such as topiramate, have been reported to cause cognitive deficits 17, 18 . A study published in 2013, evaluating 30 patients with chronic migraine and 30 healthy controls, detected a low performance in cognitive tests in patients with chronic migraine, apparently unrelated to other factors 12 
.
The results of functional MNR in patients using topiramate and controls found deficits in the language network areas. These data suggest a mechanism by which this drug impairs cognitive processing during language function, both for chronic and single dose 18 . Another double-blind controlled study, published in 2011, found that topiramate causes dose-dependent cognitive deficits after six weeks of use 19 . Thus, this study aimed to evaluate the presence of cognitive deficits in patients with a episodic migraine and to compare them with the results previously described in the literature. Also, it aimed at evaluating the main triggers of cognitive disorders present in the migraine population, such as depressive disorder, anxiety disorder, use of CNS medications such as topiramate, non-restorative sleep, alcohol abuse, history of trauma cranial and other comorbidities.
METHODS
A cross-sectional descriptive study was carried out at Centro Universitário Barão de Mauá School of Medicine, with students from this course. Students over 18 years old of both genders, with a episodic migraine with or without aura (transient neurological disorders accompanying headache) were included. The International Headache Society (IHS) criteria were followed: pain lasting 4 to 72 hours, characterized by strong intensity, throbbing or pulsatile, worsening with daily activities, and may be accompanied by symptoms such as nausea, vomiting, photophobia and phonophobia, occurring for less than 15 days in the month. The exclusion criteria were patients with brain dysfunction that prevented from responding to questionnaires, patients who did not agree to sign the Free and Informed Consent Form (FICT). Students were interviewed personally for the evaluation of demographic data and clinical data, as well as neuropsychological tests for cognitive assessment. A control group (CG) was formed, matching patients by gender, age and schooling, without a diagnosis of migraine. Considering that the previous study found significant differences in cognitive tests by the Montreal Cognitive Assessment (MoCa) applied in women with chronic migraine and controls (groups of 30 cases and 30 controls) ( Table 1) . A sample calculation was performed considering the difference between the MoCa test results among the two groups and the standard deviation of the results (Table 2) . For a test strength of 90% accuracy, it was estimated that the "migraine" and "control" groups should have at least 27 members each. Comparison between the groups was based on the Student t-test, and the equation for the sample calculation was
, where µ 1 and µ 2 are the means of the MoCa score in the groups with and without migraine, respectively, and σ is the population's standard deviation obtained from the study by Ferreira et al. All sample sizes presented here were calculated considering a bilateral hypothesis test, the highest standard deviation (2.6), with a significance level of 5% and with variations in test strength of 70 to 90% and a minimum difference of 2.3 (found in the study). 
Statistical analysis
The data were analyzed by the SPSS program version 18.0 24 .
In the categorical variables analysis, the Chi-square or Fisher's Exact test was applied, according to the expected frequency in the cells. In the numerical variables analysis, Kolmogorov-Smirnov tests were applied to define the type of variables distribution; for those that had a normal distribution, parametric tests such as the Student t test or the Variance Analysis (ANOVA) were used. The variables that did not present normal distribution were evaluated with the non-parametric Mann-Whitney test. In order to correlate two or more variables, binary logistic regression analysis, and linear regression were used.
RESULTS
A total of 64 students were approached. Three controls were excluded because they presented intense and frequent tensional headache. One student was excluded because he had no migraine attacks for more than one year. Finally, 60 students were included in the study, 30 of them with a episodic migraine and 30 controls. The demographic data of the episodic migraine group (EMG) and control group (CG) are described in table 3. Regarding the characteristics of migraine and the impact on daily and work activities, the results are described in table 4. Among the drugs used by EMG, 18 (60%) patients used contraceptives, 2 (6.7%) used topiramate, 2 (6.7%) use antidepressants, 3 (10%) used beta blockers, 1 (3.3%) used flunarizine, and 1 (3.3%) used chlorpromazine. The most commonly used analgesics were dipyrone (15-50%), ergotamine (2-6.7%) and non-hormonal anti-inflammatory (5-16.7%). The frequency of analgesic use was 4.4±4.2 days/month. Only 2 (11.1%) were abusers of ergotamine. Among the CG patients, the most used drugs were contraceptives (18-60%), antidepressants (1-3.3%).
The most common comorbidities in EMG were generalized anxiety disorder (10-33.3%), major depressive disorder (2-6.7%), hypothyroidism (3-10%), non-restorative sleep (12-40%) and hypertension (1-3.3%). There were no patients with diabetes or previous head trauma. The use of caffeine was present in 12-40% and the use of alcohol in 9-27%. The most common comorbidities in the CG were generalized anxiety disorder (6-20%), non-restorative sleep (5-16.7%), hypothyroidism (2-6.7%). No patient reported major depressive disorder, hypertension, diabetes, previous head trauma. The use of caffeine was present in 10-30% and the use of alcohol in 16-53.3%. Among the patients interviewed, 2 (6.7%) had complaints of memory impairment in the EMG and 2 (6.7%) in the CG. Regarding the applied cognitive tests, the main results are described in table 5. When applied the linear regression, using MoCa as a dependent variable and episodic migraine, anxiety disorder, depressive disorder, use of topiramate and non-restorative sleep as independent variables, none of these variables was an influencing factor in MoCa (Table 6 ). Visual pain scale (mean±SD) 8.5 ± 1.1
Pain time (years) (mean±SD) 7.0 ± 4.4
Frequency (days/month) (mean±SD) 4.5 ± 3.4 
DISCUSSION
This paper described and analyzed the cognitive aspects in patients with a episodic migraine and non-migraine controls, matched by gender, age, and schooling, as well as evaluating the main trigger factors of cognitive disorders present, such as depressive disorder, anxiety disorder, use of topiramate, non-restorative sleep.
The topic of cognition and chronic pain has been studied more recently in some papers. Landrø et al. 25 identified some possible reasons for these deficits, including the presence of depressive symptoms (which are present in 40 to 50% of patients with chronic pain) and drug use 26 . Another study, conducted by our research group, had already shown cognitive deficits in patients with chronic migraine compared to the CG 20 . A prospective study evaluated participants with migraine, with and without aura for cognitive function. Three cognitive tests were used: The Words List of the Consortium to Establish a Registry for Alzheimer Disease (CERAD), verbal fluency tests and Tracks. Patients with migraine without aura were associated with worse cognitive performance 15 . The exact mechanism supporting the complex relationship between chronic pain and cognition has not been fully understood. There is a direct relation between attention, transient retention of information, immediate memory and the activity of neurons in the prefrontal cortex. What would be the physiological basis of this finding? First of all, the same neural networks that are used for many cognitive functions are also used for nociceptive functions. Secondly, bodily sensations can lead the individual to a state of hypervigilance and divert attention from other cognitive tasks. This hampers an effective response to new information. These results support the "neurocognitive model of the dynamics of attention to pain" 6 . In this study, the EMG patients presented MoCa performance similar to the CG. There was also similar performance in the migraine group relative to the CG in the verbal fluency tests, Stroop test, and no significant statistic was found in the Mann-Whitney test. These data are different from those found in a previous study that evaluated patients with chronic migraine and a CG, finding impairments in tasks that use attention (Stroop test), language (verbal fluency) and visuospatial abilities (clock design) 20 . The results also differ from other studies that have shown cognitive alterations in patients with migraine [12] [13] [14] [15] and resemble studies that did not find this alterations [7] [8] [9] [10] [11] . However, it is believed that an evaluation with a greater number of patients could be useful to explain these results better.
Although there is a small number of patients, it is possible to work with a paired sample by gender, schooling, and age. In addition, a linear regression model was used to control possible confounding variables. These variables, such as anxiety disorder, depressive disorder, drugs use, sleep disturbances, by influencing cognition, are major challenges for clinical studies that address the issue of chronic pain. In this study, it was possible to analyze these variables that would act as confounders in the MoCa test results through linear regression. Regarding the evaluation of episodic migraine, anxiety disorder, depressive disorder, use of topiramate and non-restorative sleep, none of these variables influenced the MoCa test. Thus, this study brings new information to the pertinent literature. 
